Global economic burden of schizophrenia: a systematic review.
Global economic burden of schizophrenia: a systematic review.
复制标题
DOI：
10.2147/ndt.s96649
复制
发表时间：
2016
影响因子：
3.2
通讯作者：
Chaiyakunapruk N
中科院分区：
文献类型：
--
作者：
Chong HY;Teoh SL;Wu DB;Kotirum S;Chiou CF;Chaiyakunapruk N
精神分裂症是2013年全球25大主要残疾原因之一。尽管其患病率低，但其健康，社会和经济负担是巨大的，不仅对患者，而且对家庭，护理人员和更广泛的社会。经济负担研究中调查的疾病负担的大小是决策者决策的重要来源。本研究的目的是系统地识别集中在精神分裂症的经济负担的研究，描述所使用的方法和数据来源，并总结精神分裂症的经济负担的研究结果。使用4个电子数据库（Medline、EMBASE、PsycINFO和EconLit）对精神分裂症经济负担研究从开始到2014年8月31日进行了系统综述。本次综述共纳入56篇文章。超过80%的研究是在高收入国家进行的。大多数研究采用了回顾性和基于患病率的研究设计。一般采用自下而上的方法来确定成本，而人力资本方法则用于间接成本的估算。在高收入国家，数据库和文献是成本估算中最常用的数据来源，而在低收入和中等收入国家，图表审查和访谈是主要的数据来源。该国精神分裂症患者的年度费用从9400万美元到1020亿美元不等。间接费用占精神分裂症总费用的50%~ 85%。精神分裂症的经济负担估计为国内生产总值的0.02%至1.65%。精神分裂症患者的巨大经济负担，显示为这些患者提供的医疗服务不足。随着公众和决策者越来越认识到精神分裂症是一种负担，明智的决定是可以实现的。这导致更好的资源分配和发展政策导向的研究，这种高度致残但认识不足的精神健康疾病。
Schizophrenia is one of the top 25 leading causes of disability worldwide in 2013. Despite its low prevalence, its health, social, and economic burden has been tremendous, not only for patients but also for families, caregivers, and the wider society. The magnitude of disease burden investigated in an economic burden study is an important source to policymakers in decision making. This study aims to systematically identify studies focusing on the economic burden of schizophrenia, describe the methods and data sources used, and summarize the findings of economic burden of schizophrenia. A systematic review was performed for economic burden studies in schizophrenia using four electronic databases (Medline, EMBASE, PsycINFO, and EconLit) from inception to August 31, 2014. A total of 56 articles were included in this review. More than 80% of the studies were conducted in high-income countries. Most studies had undertaken a retrospective- and prevalence-based study design. The bottom-up approach was commonly employed to determine cost, while human capital method was used for indirect cost estimation. Database and literature were the most commonly used data sources in cost estimation in high-income countries, while chart review and interview were the main data sources in low and middle-income countries. Annual costs for the schizophrenia population in the country ranged from US$94 million to US$102 billion. Indirect costs contributed to 50%–85% of the total costs associated with schizophrenia. The economic burden of schizophrenia was estimated to range from 0.02% to 1.65% of the gross domestic product. The enormous economic burden in schizophrenia is suggestive of the inadequate provision of health care services to these patients. An informed decision is achievable with the increasing recognition among public and policymakers that schizophrenia is burdensome. This results in better resource allocation and the development of policy-oriented research for this highly disabling yet under-recognized mental health disease.